Company profile
NeurogesX, Inc. (dissolved/wound down)
Privately held: no public share price (Formerly NASDAQ-listed (NGSX); delisted to the OTCBB in 2012 for falling below the $50M market-value requirement, then sold substantially all assets (including Qutenza and NP-1998) to Acorda Therapeutics in July 2013 and distributed remaining cash to shareholders. The company ceased operating as a going concern; recorded as private since it no longer trades on any public market and there is no surviving public successor carrying its identity forward. Sources: https://clinicaltrials.gov/study/NCT00082316 ; https://www.globenewswire.com/news-release/2012/04/20/473874/16630/en/NeurogesX-Receives-Determination-Letter-From-NASDAQ.html ; https://www.sec.gov/Archives/edgar/data/0001385830/000119312513090889/d483678d8k.htm Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Capsaicin (Qutenza)(Qutenza) | Approved | TRPV1 (transient receptor potential vanilloid 1) channelSmall molecule | Diabetic Peripheral Neuropathic Pain |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.